Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance ...

WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...

On Tuesday, Wolfe Research began coverage on Spyre (NASDAQ:SYRE), assigning the biopharmaceutical company an Outperform rating. The firm’s analyst, Andy Chen, provided a positive outlook based ...

Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations ...

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com .

WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, ...

Spyre Therapeutics has a 52 week low of $17.24 and a 52 week high of $47.97. The business’s fifty day simple moving average is $21.65 and its 200-day simple moving average is $26.41.

On Tuesday, Wolfe Research began coverage on Spyre (NASDAQ:SYRE), assigning the biopharmaceutical company an Outperform rating. The firm’s analyst, Andy Chen, provided a positive outlook based on ...

Finally, Robert W. Baird boosted their price objective on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th.